Disclosures: Nicholas Prescott: Nothing to Disclose, Andres Mansisidor: Nothing to Disclose, Yaron Bram: Nothing to Disclose, Christine Lim: Nothing to Disclose, Viviana Risca: Nothing to Disclose, Yael David: Nothing to Disclose, Robert Schwartz: Miromatrix Inc: Advisor, Lime Therapeutics: Advisor, Otsuka Inc.: Grant/Research Support, Alnylam Pharmaceuticals: Speaking and Teaching, Alnylam Pharmaceuticals: Consultant 722 IMPROVEMENTS IN PRURITUS ARE ASSOCIATED WITH IMPROVEMENTS IN GROWTH IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: DATA FROM THE MARCH-ON TRIAL Alexander Miethke 1 Amal Aqul 2 Chuan-Hao Lin 3 Douglas Mogul 4 Tiago Nunes 4 Jolan Terner-Rosenthal 4 Marshall Baek 4 Pamela Vig 4 Richard Thompson 5 , 1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2 University of Texas Southwestern Medical Center, Dallas, Texas, 3 Children's Hospital Los Angeles, Los Angeles, California, 4 Mirum Pharmaceuticals, Inc., Foster City, California, 5 King's College London, United Kingdom Background: Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders resulting in disrupted bile composition and cholestasis leading to debilitating pruritus, growth deficits, vitamin deficiency, and progressive liver damage
Due to increased iron intake and decreased iron excretion, increased intracellular liberation of Fe 2+ activates the ferroptosis pathway
A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility
Castelli S, Ciccarone F, Tavian D, Ciriolo MR
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
